Does cardiovascular protection translate into renal protection?

Nature Reviews Cardiology

Volumn 11, Issue 12, 2014, Pages 742-746

  Ruiz Hurtado, Gema ^a   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; MINERALOCORTICOID ANTAGONIST; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; CARDIOVASCULAR DISEASES; COMPLICATION; DISEASE COURSE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; RISK REDUCTION;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84927570177     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2014.97     Document Type: Review

References (45)

1. Ruilope, L. M. & Bakris, G. L. Renal function and target organ damage in hypertension. Eur. Heart J. 32, 1599-1604 (2011).
2. Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382, 339-352 (2013).
3. Samuelsson, O. Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care. Acta Med. Scand. Suppl. 702, 1-79 (1985).
4. Shulman, N. B. et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-Up Program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13 (5 Suppl.), I80-I93 (1989).
5. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. Suppl. [online], http://www.kdigo.org/clinical-practice-guidelines/pdf/KDIGO-BP-GL.pdf (2012).
6. Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807-814 (2012).
7. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. Suppl. [online], http://www.kdigo.org/clinical-practice-guidelines/Lipids/KDIGO%20Lipid%20Management%20Guideline%202013.pdf (2013).
8. Nitsch, D. et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 346, f324 (2013).
9. Research News: Low eGFR and high albuminuria predict end stage kidney disease and death at all ages. BMJ 345, e7478 (2012).
10. Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
11. Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
12. Ruilope, L. M. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 12, 218-225 (2001).
13. Mann, J. F., Gerstein, H. C., Pogue, J., Bosch, J. & Yusuf, S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629-636 (2001).
14. Rahman, M. et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch. Intern. Med. 165, 936-946 (2005).
15. Mann, J. F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
16. Lawes, C. M., Vander Hoorn, S. & Rodgers, A. for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371, 1513-1518 (2008).
17. Huang, Y. et al. Prehypertension and incidence of ESRD: a systematic review and meta-analysis. Am. J. Kidney Dis. 63, 76-83 (2014).
18. Banegas, J. R. et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehu016.
19. Mancia, G. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34, 2159-2219 (2013).
20. Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895-906 (2005).
21. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007).
22. de Galan, B. E. et al. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 20, 883-892 (2009).
23. Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
24. Bakris, G. L. et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173-1181 (2010).
25. Zanchetti, A. et al. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J. Hypertens. 27, 673-679 (2009).
26. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
27. Ruilope, L. M., Segura, J., Fujita, T. & Ritz, E. Renal and cardiovascular events: do they deserve the same consideration in clinical trials? J. Hypertens. 27, 1743-1745 (2009).
28. Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
29. Fried, L. F. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 369, 1892-1903 (2013).
30. James, P. A. et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507-520 (2014).
31. Weber, M. A. et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J. Clin. Hypertens. (Greenwich) 16, 14-26 (2014).
32. de Zeeuw, D. et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110, 921-927 (2004).
33. Schmieder, R. E. et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J. Am. Soc. Nephrol. 22, 1353-1364 (2011).
34. Estruch, R. et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279-1290 (2013).
35. Dunkler, D. et al. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern. Med. 173, 1682-1692 (2013).
36. Wing, R. R. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N. Engl. J. Med. 369, 145-154 (2013).
37. Sarafidis, P. A. & Ruilope, L. M. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Kidney Int. 85, 536-546 (2014).
38. Ruilope, L. M. Chronic kidney disease: Blood pressure control in CKD-still a matter of debate. Nat. Rev. Nephrol. 9, 572-573 (2013).
39. Van Buren, P. N., Adams-Huet, B., Nguyen, M., Molina, C. & Toto, R. D. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Clin. J. Am. Soc. Nephrol. 9, 295-301 (2014).
40. Jardine, M. J. et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J. Am. Coll. Cardiol. 56, 956-965 (2010).
41. Ninomiya, T. et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 347, f5680 (2013).
42. Gorostidi, M. et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5, 693-patient cross-sectional analysis from Spain. Am. J. Kidney Dis. 62, 285-294 (2013).
43. Formentini, I. et al. Current drug development challenges in chronic kidney disease (CKD)-identification of individualized determinants of renal progression and premature cardiovascular disease (CVD). Nephrol. Dial. Transplant. 27 (Suppl. 3), iii81-iii88 (2012).
44. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 39 (2 Suppl. I), S1-S266 (2002).
45. Kidney Disease: Improving Global Outcomes Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. [online], http://www.kdigo.org/clinical-practice-guidelines/pdf/CKD/KDIGO-2012-CKD-GL.pdf (2013)